Terrance P. Coyne, Executive Vice President and Chief Financial Officer of Royalty Pharma plc (NASDAQ:RPRX), filed a Form 4 on November 6, 2026, disclosing multiple changes in beneficial ownership of Class A Ordinary Shares and limited partnership interests in RPI US Partners 2019, LP, with transactions dated November 4 and November 6, 2026.

Key Highlights

  • Equity Performance Award settlement: Coyne acquired 7,122 Class A Ordinary Shares on November 4, 2026, indirectly through TPC RP EPA1 LLC, at a price of $0, described as an exempt acquisition in connection with the settlement of Equity Performance Awards under Rule 16b-3.
  • Exchange of LP interests (TPC RP 2021, LLC): On November 6, 2026, 15,000 RPI US Partners 2019, LP interests held by TPC RP 2021, LLC were converted (transaction code C) into 150,000 Class A Ordinary Shares at $0, leaving 102,526 LP interests remaining in that entity.
  • Exchange of LP interests (TPC RP, LLC): On November 6, 2026, 10,000 RPI US Partners 2019, LP interests held by TPC RP, LLC were converted (transaction code C) into 100,000 Class A Ordinary Shares at $0, leaving 473,942 LP interests remaining in that entity.
  • Additional indirect holdings disclosed: The filing reports 24,170 shares held by a spouse's IRA, 23,270 shares held by Coyne's own IRA, 1,500 shares held directly, 1,450 shares held by spouse, and 43,350 LP interests held by TPC ICAI, LLC (convertible into 433,500 Class A Ordinary Shares).
  • Class E Ordinary Shares noted: According to the filing's remarks, Coyne also holds Class E Ordinary Shares of Royalty Pharma Holdings Limited exchangeable into 1,788,777 Class A Ordinary Shares, which "are subject to vesting conditions."
  • No additional value paid: The filing states that the exchanges of LP interests for Class A Ordinary Shares were made "pursuant to the terms of the Amended and Restated Exchange Agreement" and that "no additional value will be paid by the Reporting Person in connection with the exchange."

CFO Coyne's November 2026 Exchange Transactions at Royalty Pharma

According to the Form 4 filing, Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, reported two categories of transactions. The first, dated November 4, 2026, was the acquisition of 7,122 Class A Ordinary Shares indirectly through TPC RP EPA1 LLC at $0, which the filing describes as an "exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards."

The second category, dated November 6, 2026, involved the conversion of limited partnership interests in RPI US Partners 2019, LP into Class A Ordinary Shares. The filing explains the mechanics: each LP interest is first exchangeable for ten Class B Interests in Royalty Pharma Holdings Limited, and each such Class B Interest is then exchangeable for one Class A Ordinary Share of the issuer. This two-step process resulted in TPC RP 2021, LLC receiving 150,000 Class A Ordinary Shares (from 15,000 LP interests) and TPC RP, LLC receiving 100,000 Class A Ordinary Shares (from 10,000 LP interests), both at $0 consideration.

The filing additionally discloses that TPC ICAI, LLC holds 43,350 LP interests in RPI US Partners 2019, LP, which the filing states are convertible into 433,500 Class A Ordinary Shares. The Form 4 was signed on November 6, 2026, by Sean Weisberg as Attorney-in-Fact for Terrance P. Coyne.

What Was Disclosed

The filing disclosed changes in Terrance P. Coyne's beneficial ownership of Royalty Pharma plc Class A Ordinary Shares and RPI US Partners 2019, LP interests across transactions on November 4 and November 6, 2026, including an equity award settlement and two LP-interest-to-share conversions, all at $0 consideration.